Compare MMLP & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMLP | VANI |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.6M | 81.2M |
| IPO Year | 2002 | 2014 |
| Metric | MMLP | VANI |
|---|---|---|
| Price | $2.60 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 12.8K | ★ 178.2K |
| Earning Date | 10-15-2025 | 11-13-2025 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $713,263,000.00 | N/A |
| Revenue This Year | $4.19 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.49 | $0.91 |
| 52 Week High | $4.02 | $1.92 |
| Indicator | MMLP | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 48.18 |
| Support Level | $2.55 | $1.25 |
| Resistance Level | $2.62 | $1.40 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 60.00 |
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.